全文获取类型
收费全文 | 991篇 |
免费 | 74篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 36篇 |
妇产科学 | 12篇 |
基础医学 | 134篇 |
口腔科学 | 18篇 |
临床医学 | 67篇 |
内科学 | 213篇 |
皮肤病学 | 14篇 |
神经病学 | 63篇 |
特种医学 | 181篇 |
外科学 | 76篇 |
综合类 | 38篇 |
预防医学 | 31篇 |
眼科学 | 7篇 |
药学 | 68篇 |
中国医学 | 7篇 |
肿瘤学 | 108篇 |
出版年
2023年 | 10篇 |
2021年 | 13篇 |
2020年 | 6篇 |
2019年 | 15篇 |
2018年 | 8篇 |
2017年 | 6篇 |
2016年 | 29篇 |
2015年 | 58篇 |
2014年 | 25篇 |
2013年 | 31篇 |
2012年 | 37篇 |
2011年 | 43篇 |
2010年 | 40篇 |
2009年 | 49篇 |
2008年 | 39篇 |
2007年 | 29篇 |
2006年 | 31篇 |
2005年 | 34篇 |
2004年 | 32篇 |
2003年 | 35篇 |
2002年 | 28篇 |
2001年 | 17篇 |
2000年 | 17篇 |
1999年 | 26篇 |
1998年 | 29篇 |
1997年 | 44篇 |
1996年 | 35篇 |
1995年 | 32篇 |
1994年 | 25篇 |
1993年 | 24篇 |
1992年 | 4篇 |
1991年 | 10篇 |
1990年 | 14篇 |
1989年 | 25篇 |
1988年 | 18篇 |
1987年 | 15篇 |
1986年 | 15篇 |
1985年 | 11篇 |
1984年 | 10篇 |
1983年 | 10篇 |
1982年 | 10篇 |
1981年 | 9篇 |
1980年 | 9篇 |
1979年 | 7篇 |
1978年 | 6篇 |
1977年 | 4篇 |
1976年 | 10篇 |
1975年 | 4篇 |
1972年 | 5篇 |
1932年 | 3篇 |
排序方式: 共有1075条查询结果,搜索用时 15 毫秒
31.
Summary
Bone marrow suppression is an important adverse reaction to most betalactam antibiotics. Recently it was suggested that piperacillin/tazobactam
(PT) also may cause bone marrow toxicity. We retrospectively analyzed 100 IV antibiotic treatment courses (mean duration 12.5
days) in 38 patients (median age 14 years) with cystic fibrosis (CF) who were treated in our hospital. Of the patients receiving
PT (84%), 6 patients (18.75% of PT-treated patients, 10.3% of PT treatment courses) developed fever, malaise and headache
during treatment without signs of acute infection. In one patient definite thrombocytopenia and neutropenia, in two others
a milder decrease in leukocyte and thrombocyte counts was observed after the onset of fever. The events were time- and dose-dependent
occurring between day 11 and 15 of treatment. Treatment courses lasted longer (14.2 vs 11.3 days; p < 0.05) and patients had
received a higher cumulative dose of PT (4919 ± 1975 mg/kg b.w. vs 3161 ± 1635 mg/kg; p < 0.02, Student's t-test) in the affected
group than in the unaffected group. After discontinuation of PT, fever subsided within 24 h and blood cell counts normalized.
We hypothesize that these fever episodes and changes of blood parameters are related to PT therapy.
Received: February 8, 1999 · Accepted: September 17, 1999 相似文献
32.
KA Hodgkinson SP Connors N Merner A Haywood T‐L Young WJ McKenna B Gallagher F Curtis AS Bassett PS Parfrey 《Clinical genetics》2013,83(4):321-331
To determine the phenotype and natural history of a founder genetic subtype of autosomal dominant arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by a p.S358L mutation in TMEM43. The age of onset of cardiac symptoms, clinical events and test abnormalities were studied in 412 subjects (258 affected and 154 unaffected), all of which occurred in affected males significantly earlier and more often than unaffected males. Affected males were hospitalized four times more often than affected females (p ≤ 0.0001) and died younger (p ≤ 0.001). The temporal sequence from symptoms onset to death was prolonged in affected females by 1–2 decades. The most prevalent electrocardiogram (ECG) manifestation was poor R wave progression (PRWP), with affected males twice as likely to develop PRWP as affected females (p ≤ 0.05). Left ventricular enlargement (LVE) occurred in 43% of affected subjects, with 11% fulfilling criteria for dilated cardiomyopathy. Ventricular ectopy on Holter monitor was common and occurred early: the most diagnostically useful clinical test. No symptom or test could rule out diagnosis. This ARVC subtype is a sex‐influenced lethal arrhythmogenic cardiomyopathy, with a unique ECG finding, LV dilatation, heart failure and early death, where molecular pre‐symptomatic diagnosis has the greatest clinical utility. 相似文献
33.
34.
35.
36.
37.
Molecular characterization of human factor XSan Antonio 总被引:1,自引:0,他引:1
Enzymatic amplification technique was used to isolate all eight exons and sequences around the splice junctions, putative promoter, and polyadenylation sites of human factor X DNA from a patient with factor X deficiency. Two genetic changes in factor X have been observed in this patient. The patient is most likely a compound heterozygote since there is only 14% activity associated with factor X. A point mutation that resulted in the substitution of cysteine (TGC) for arginine (CGC) at amino acid 366 was found in exon VIII of one allele of the factor X gene. This mutation, which occurs in the catalytic domain, can affect the formation of a disulfide bridge and thus could result in a reduction in factor X activity. Sequencing all the regions revealed a second mutation: a deletion of one nucleotide (TCCT to TCT) in exon VII that would cause a frame shift at amino acid 272 followed by termination. We have also shown that the point mutation in exon VIII creates an ApaL1 restriction site and destroys the HinP1 site. Enzymatic DNA amplification followed by restriction digestion provides a quick, reliable, and sensitive method for carrier detection and antenatal diagnosis in affected kindreds. This is the first characterization of factor X deficiency at the molecular level. We propose to name this mutation Factor XSan Antonio. 相似文献
38.
Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients 总被引:5,自引:1,他引:5
Mannucci PM; Bauer KA; Santagostino E; Faioni E; Barzegar S; Coppola R; Rosenberg RD 《Blood》1994,84(4):1314-1319
Virally inactivated, high-purity factor XI concentrates are available for treatment of patients with factor XI deficiency. However, preliminary experience indicates that some preparations may be thrombogenic. We evaluated whether a highly purified concentrate produced signs of activation of the coagulation cascade in two patients with severe factor XI deficiency infused before and after surgery. Signs of heightened enzymatic activity of the common pathway of coagulation (elevated plasma levels of prothrombin fragment 1 + 2 and fibrinopeptide A) developed in the early post-infusion period, accompanied by more delayed signs of fibrin formation with secondary hyperfibrinolysis (elevated D-dimer and plasmin-antiplasmin complex). These changes occurred in both patients, but were more severe in the older patient with breast cancer when she underwent surgery, being accompanied by fibrinogen and platelet consumption. There were no concomitant signs of heightened activity of the factor VII-tissue factor mechanism on the factor Xase complex (plasma levels of activated factor VII and of factor IX and X activation peptides did not increase). The observed changes in biochemical markers of coagulation activation indicate that concentrate infusions increased thrombin generation and activity and that such changes were magnified by malignancy and surgery. Because some factor XI concentrates may be thrombogenic, they should be used with caution, especially in patients with other risk factors for thrombosis. 相似文献
39.
Florian Grahammer Nora Haenisch Frederic Steinhardt Lukas Sandner Malte Roerden Frederic Arnold Tomke Cordts Nicola Wanner Wilfried Reichardt Dontscho Kerjaschki Markus A. Ruegg Michael N. Hall Pierre Moulin Hauke Busch Melanie Boerries Gerd Walz Ferruh Artunc Tobias B. Huber 《Proceedings of the National Academy of Sciences of the United States of America》2014,111(27):E2817-E2826
40.
Nils Schweingruber Henrike J. Fischer Lisa Fischer Jens van den Brandt Anna Karabinskaya Verena Labi Andreas Villunger Benedikt Kretzschmar Peter Huppke Mikael Simons Jan P. Tuckermann Alexander Flügel Fred Lühder Holger M. Reichardt 《Acta neuropathologica》2014,127(5):713-729
Glucocorticoids (GCs) are the standard therapy for treating multiple sclerosis (MS) patients suffering from an acute relapse. One of the main mechanisms of GC action is held to be the induction of T cell apoptosis leading to reduced lymphocyte infiltration into the CNS, yet our analysis of experimental autoimmune encephalomyelitis (EAE) in three different strains of genetically manipulated mice has revealed that the induction of T cell apoptosis is not essential for the therapeutic efficacy of GCs. Instead, we identified the redirection of T cell migration in response to chemokines as a new therapeutic principle of GC action. GCs inhibited the migration of T cells towards CCL19 while they enhanced their responsiveness towards CXCL12. Importantly, blocking CXCR4 signaling in vivo by applying Plerixafor® strongly impaired the capacity of GCs to interfere with EAE, as revealed by an aggravated disease course, more pronounced CNS infiltration and a more dispersed distribution of the infiltrating T cells throughout the parenchyma. Our observation that T cells lacking the GC receptor were refractory to CXCL12 further underscores the importance of this pathway for the treatment of EAE by GCs. Importantly, methylprednisolone pulse therapy strongly increased the capacity of peripheral blood T cells from MS patients of different subtypes to migrate towards CXCL12. This indicates that modulation of T cell migration is an important mechanistic principle responsible for the efficacy of high-dose GC therapy not only of EAE but also of MS. 相似文献